Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
[PubMed] [Google Scholar] Potter D
Abstract Purpose of Review The glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) liraglutide and semaglutide, and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA tirzepatide are approved for the treatment of overweight and obesity
doi:10.1080/17425255.2021.1955856 43
Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, Bismuth K, Jacques C, Berenbaum F (2022) Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis
US$ 28.15
US$ 27.34
US$ 27.24
US$ 21.29
US$ 29.32
US$ 24.97
US$ 20.79
US$ 25.41
US$ 22.31
US$ 23.39
